Key result
Ginsenoside Rd attenuates doxorubicin-induced cardiomyocyte apoptosis and inflammation via the MIR100HG/miR-498/SMURF2 axis.
Why the study?
Doxorubicin can cause irreversible cardiac damage and heart failure, and although ginsenoside Rd has shown benefits in cardiac diseases, its protective role in doxorubicin-induced cardiomyocyte injury remained unclear.
Does ginsenoside Rd attenuate doxorubicin-induced cardiomyocyte apoptosis and inflammation in human AC16 cells in vitro?
Does ginsenoside Rd attenuate doxorubicin-induced cardiomyocyte apoptosis and inflammation in human AC16 cells in vitro?
This in vitro study identifies that ginsenoside Rd protects human cardiomyocytes against doxorubicin-induced apoptosis and inflammation by modulating the MIR100HG/miR-498/SMURF2 signaling axis, suggesting a potential therapeutic target for anthracycline cardiotoxicity.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications for doxorubicin cardiotoxicity; leaves open in vivo validation of the MIR100HG/miR-498/SMURF2 axis.
Doxorubicin (DOX) is an anthracycline antibiotic widely used to treat various cancers. Nevertheless, DOX can cause irreversible cardiac damage and lead to heart failure. Previous evidence has indicated the benefits of ginsenoside Rd (GRd) on cardiac diseases; however, whether GRd has a protective role in DOX-induced cardiomyocyte injury is unclear. The human AC16 cardiomyocyte cell line was stimulated with DOX to mimic the microenvironment of heart failure in vitro. CCK-8 assay, flow cytometry, and TUNEL staining were utilized for cell viability and apoptosis analysis, respectively. ELISA examined the concentrations of inflammatory factors and the myocardial injury marker. Western blotting and RT-qPCR were employed for protein or RNA expression detection, respectively. Luciferase reporter assay, RNA immunoprecipitation, and fluorescence in situ hybridization were implemented to verify the interaction between SMURF2, miR-498, and MIR100HG. The results showed that GRd treatment restored AC16 cell viability and attenuated DOX-triggered apoptosis, inflammatory cytokine production, and cardiac injury marker expression. GRd downregulated MIR100HG and SMURF2 expression in DOX-treated AC16 cells. SMURF2 was targeted by miR-498, and MIR100HG bound to miR-498. Overexpressing SMURF2 counteracted MIR100HG silencing-mediated attenuation of apoptosis and inflammatory response in DOX-stimulated AC16 cells. Overexpressing MIR100HG or SMURF2 reversed the above effects caused by GRd. In conclusion, GRd ameliorates DOX-triggered cardiomyocyte injury by reducing apoptosis and inflammation via the MIR100HG/miR-498/SMURF2 axis.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied Doxorubicin-induced cardiomyocyte injury / Heart failure (in vitro model). Ginsenoside Rd (GRd) vs. Doxorubicin (5 μM) alone / Untreated control cells was evaluated on AC16 cardiomyocyte cell viability, apoptosis, and inflammatory cytokine levels (p=<0.05). Ginsenoside Rd (50 μM) restored cell viability and attenuated apoptosis and inflammation in doxorubicin-stimulated human AC16 cardiomyocytes via the MIR100HG/miR-498/SMURF2 axis.
Synapse has enriched 10 related papers. Consider them for comparative context: